{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T17:36:10Z","timestamp":1788802570052,"version":"build-2803163510"},"reference-count":31,"publisher":"Japanese Society of Toxicology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Toxicol. Sci."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2131\/jts.42.519","type":"journal-article","created":{"date-parts":[[2017,7,13]],"date-time":"2017-07-13T22:34:36Z","timestamp":1499985276000},"page":"519-527","source":"Crossref","is-referenced-by-count":25,"title":["Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes"],"prefix":"10.2131","volume":"42","author":[{"given":"Hitoshi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayoi","family":"Honda","sequence":"additional","affiliation":[{"name":"Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Deguchi","sequence":"additional","affiliation":[{"name":"Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Yamada","sequence":"additional","affiliation":[{"name":"Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoko","family":"Bando","sequence":"additional","affiliation":[{"name":"Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"898","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Abi-Gerges, N., Pointon, A., Oldman, K.L., Brown, M.R., Pilling, M.A., Sefton, C.E., Garside, H. and Pollard, C.E. (2017): Assessment of extracellular field potential and Ca2+ transient signals for early QT\/pro-arrhythmia detection using human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods, <b>83<\/b>, 1-15.","DOI":"10.1016\/j.vascn.2016.09.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Chadha, S., Lodha, A., Shetty, V., Sadiq, A., Hollander, G. and Shani, J. (2011): A case of 2:1 atrio - ventricular block in digoxin toxicity. J. Clinic. Experiment. Cardiol., <b>2<\/b>, 154.","DOI":"10.4172\/2155-9880.1000154"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Demiry\u00fcrek, A.T. and Demiry\u00fcrek, S. (2005): Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton. Autacoid. Pharmacol., <b>25<\/b>, 35-52.","DOI":"10.1111\/j.1474-8673.2004.00334.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Dempsey, G.T., Chaudhary, K.W., Atwater, N., Nguyen, C., Brown, B.S., McNeish, J.D., Cohen, A.E. and Kralj, J.M. (2016): Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. J. Pharmacol. Toxicol. Methods, <b>81<\/b>, 240-250.","DOI":"10.1016\/j.vascn.2016.05.003"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Guo, L., Dong, Z. and Guthrie, H. (2009): Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates. J. Pharmacol. Toxicol. Methods, <b>60<\/b>, 130-151.","DOI":"10.1016\/j.vascn.2009.07.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Guo, L., Abrams, R.M., Babiarz, J.E., Cohen, J.D., Kameoka, S., Sanders, M.J., Chiao, E. and Kolaja, K.L. (2011): Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci., <b>123<\/b>, 281-289.","DOI":"10.1093\/toxsci\/kfr158"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Harms, H.H. (1976): Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J. Pharmacol. Exp. Ther., <b>199<\/b>, 329-335.","DOI":"10.1016\/S0022-3565(25)30687-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Hayakawa, T., Kunihiro, T., Ando, T., Kobayashi, S., Matsui, E., Yada, H., Kanda, Y., Kurokawa, J. and Furukawa, T. (2014): Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology. J. Mol. Cell. Cardiol., <b>77<\/b>, 178-191.","DOI":"10.1016\/j.yjmcc.2014.09.010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Ikeda, S., Oka, H., Matunaga, K., Kubo, S., Asai, S., Miyahara, Y., Osaka, A. and Kohno, S. (1998): Astemizole-induced torsades de pointes in a patient with vasospastic angina. Jpn. Circ. J., <b>62<\/b>, 225-227.","DOI":"10.1253\/jcj.62.225"},{"key":"10","unstructured":"Ito, M., Tanaka, T., Saitoh, M., Masuoka, H., Nakano, T. and Hidaka, H. (1988): Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine. Biochem. Pharmacol., <b>37<\/b>, 2041-2044."},{"key":"11","unstructured":"Jenzer, H.R. and Hagemeijer, F. (1976): Quinidine syncope: torsade de pointes with low quinidine plasma concentrations. Eur. J. Cardiol., <b>4<\/b>, 447-451."},{"key":"12","doi-asserted-by":"crossref","unstructured":"Katritsis, D., Morgan, J., Brachmann, J., Bygrave, A., O&apos;Farrell, D., Rowland, E. and Camm, A.J. (1997): Electrophysiological effects of E 4031, a drug with selective class III properties, in man. Pacing. Clin. Electrophysiol., <b>20<\/b>, 930-937.","DOI":"10.1111\/j.1540-8159.1997.tb05496.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kitaguchi, T., Moriyama, Y., Taniguchi, T., Ojima, A., Ando, H., Uda, T., Otabe, K., Oguchi, M., Shimizu, S., Saito, H., Morita, M., Toratani, A., Asayama, M., Yamamoto, W., Matsumoto, E., Saji, D., Ohnaka, H., Tanaka, K., Washio, I. and Miyamoto, N. (2016): CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities. J. Pharmacol. Toxicol. Methods., <b>78<\/b>, 93-102.","DOI":"10.1016\/j.vascn.2015.12.002"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Krapf, R. and Gertsch, M. (1985): Torsade de pointes induced by sotalol despite therapeutic plasma sotalol concentrations. Br. Med. J. (Clin. Res. Ed.), <b>290<\/b>, 1784-1785.","DOI":"10.1136\/bmj.290.6484.1784-a"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lu, H.R., Whittaker, R., Price, J.H., Vega, R., Pfeiffer, E.R., Cerignoli, F., Towart, R. and Gallacher, D.J. (2015): High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds. Toxicol. Sci., <b>148<\/b>, 503-516.","DOI":"10.1093\/toxsci\/kfv201"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Mellor, H.R., Bell, A.R., Valentin, J.P. and Roberts, R.R. (2011): Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci., <b>120<\/b>, 14-32.","DOI":"10.1093\/toxsci\/kfq378"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J. and Cantilena, L.R.Jr. (1990): Torsades de pointes occurring in association with terfenadine use. JAMA, <b>264<\/b>, 2788-2790.","DOI":"10.1001\/jama.1990.03450210088038"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Nozaki, Y., Honda, Y., Watanabe, H., Saiki, S., Koyabu, K., Itoh, T., Nagasawa, C., Nakamori, C., Nakayama, C., Iwasaki, H., Suzuki, S., Washio, I., Takahashi, E., Miyamoto, K., Yamanishi, A., Endo, H., Shinozaki, J., Nogawa, H. and Kunimatsu, T. (2016): CSAHi study: Validation of multi-electrode array systems (MEA60\/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability. Regul. Toxicol. Pharmacol., <b>77<\/b>, 75-86.","DOI":"10.1016\/j.yrtph.2016.02.007"},{"key":"19","unstructured":"O&apos;Hara, T. and Rudy, Y. (2012): Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species. Am. J. Physiol. Heart Circ. Physiol., <b>302<\/b>, H1023-1030."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Ohki, R., Takahashi, M., Mizuno, O., Fujikawa, H., Mitsuhashi, T., Katsuki, T., Ikeda, U. and Shimada, K. (2001): Torsades de pointes ventricular tachycardia induced by mosapride and flecainide in the presence of hypokalemia. Pacing. Clin. Electrophysiol., <b>24<\/b>, 119-121.","DOI":"10.1046\/j.1460-9592.2001.00119.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Pointon, A., Harmer, A.R., Dale, I.L., Abi-Gerges, N., Bowes, J., Pollard, C. and Garside, H. (2015): Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci., <b>144<\/b>, 227-237.","DOI":"10.1093\/toxsci\/kfu312"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Redfern, W.S., Carlsson, L., Davis, A.S., Lynch, W.G., MacKenzie, I., Palethorpe, S., Siegl, P.K., Strang, I., Sullivan, A.T., Wallis, R., Camm, A.J. and Hammond, T.G. (2003): Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., <b>58<\/b>, 32-45.","DOI":"10.1016\/S0008-6363(02)00846-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Roden, D.M. (2004): Drug-induced prolongation of the QT interval. N.Engl. J. Med., <b>350<\/b>, 1013-1022.","DOI":"10.1056\/NEJMra032426"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Scott, C.W., Zhang, X., Abi-Gerges, N., Lamore, S.D., Abassi, Y.A. and Peters, M.F. (2014): An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility. Toxicol. Sci., <b>142<\/b>, 331-338.","DOI":"10.1093\/toxsci\/kfu186"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Sinnecker, D., Laugwitz, K.L. and Moretti, A. (2014): Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing. Pharmacol. Ther., <b>143<\/b>, 246-252.","DOI":"10.1016\/j.pharmthera.2014.03.004"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y.W., Funes, C., Rusyn, I., Anson, B. and Cromwell, E.F. (2013a): Multiparameter <i>in vitro<\/i> assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen., <b>18<\/b>, 39-53.","DOI":"10.1177\/1087057112457590"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Sirenko, O., Cromwell, E.F., Crittenden, C., Wignall, J.A., Wright, F.A. and Rusyn, I. (2013b): Assessment of beating parameters in human induced pluripotent stem cells enables quantitative <i>in vitro<\/i> screening for cardiotoxicity. Toxicol. Appl. Pharmacol., <b>273<\/b>, 500-507.","DOI":"10.1016\/j.taap.2013.09.017"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Valentin, J.P., Hoffmann, P., De Clerck, F., Hammond, T.G. and Hondeghem, L. (2004): Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J. Pharmacol. Toxicol. Methods., <b>49<\/b>, 171-181.","DOI":"10.1016\/j.vascn.2004.03.008"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Yang, T., Snyders, D. and Roden, D.M. (2001): Drug block of I(kr): model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol., <b>38<\/b>, 737-744.","DOI":"10.1097\/00005344-200111000-00010"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Yokoo, N., Baba, S., Kaichi, S., Niwa, A., Mima, T., Doi, H., Yamanaka, S., Nakahata, T. and Heike, T. (2009): The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem. Biophys. Res. Commun., <b>387<\/b>, 482-488.","DOI":"10.1016\/j.bbrc.2009.07.052"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Zeng, H., Roman, M.I., Lis, E., Lagrutta, A. and Sannajust, F. (2016): Use of FDSS\/\u03bcCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes. J. Pharmacol. Toxicol. Methods., <b>81<\/b>, 217-222.","DOI":"10.1016\/j.vascn.2016.05.009"}],"container-title":["The Journal of Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/42\/4\/42_519\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T19:37:46Z","timestamp":1750621066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jts\/42\/4\/42_519\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2131\/jts.42.519","relation":{},"ISSN":["0388-1350","1880-3989"],"issn-type":[{"value":"0388-1350","type":"print"},{"value":"1880-3989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}